These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37651087)

  • 1. Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma.
    Peterse EFP; Verburg-Baltussen EJM; Stewart A; Liu FF; Parker C; Treur M; Malcolm B; Klijn SL
    Pharmacoecon Open; 2023 Nov; 7(6):941-950. PubMed ID: 37651087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Advanced Flexible Modeling Approaches for Survival Extrapolation from Early Follow-up Data in two Nivolumab Trials in Advanced NSCLC with Extended Follow-up.
    Chaudhary MA; Edmondson-Jones M; Baio G; Mackay E; Penrod JR; Sharpe DJ; Yates G; Rafiq S; Johannesen K; Siddiqui MK; Vanderpuye-Orgle J; Briggs A
    Med Decis Making; 2023 Jan; 43(1):91-109. PubMed ID: 36259353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma.
    Klijn SL; Fenwick E; Kroep S; Johannesen K; Malcolm B; Kurt M; Kiff C; Borrill J
    Pharmacoeconomics; 2021 Mar; 39(3):345-356. PubMed ID: 33428174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.
    Vadgama S; Mann J; Bashir Z; Spooner C; Collins GP; Bullement A
    Value Health; 2022 Jun; 25(6):1010-1017. PubMed ID: 35667774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
    Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
    J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
    Federico Paly V; Kurt M; Zhang L; Butler MO; Michielin O; Amadi A; Hernlund E; Johnson HM; Kotapati S; Moshyk A; Borrill J
    MDM Policy Pract; 2022; 7(1):23814683221089659. PubMed ID: 35356551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis.
    Puckrin R; Stewart DA; Shafey M
    Transplant Cell Ther; 2022 Apr; 28(4):218.e1-218.e4. PubMed ID: 35123117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of
    Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
    J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.
    Bastos-Oreiro M; Gutierrez A; Iacoboni G; López Corral L; Reguera JL; Abrisqueta P; Delgado J; Terol MJ; Hernani R; Martínez N; Ortíz V; Bailen R; Gomez-Centurión I; Caballero A; Sanz J; Guerra Domínguez L; Luzardo H; Mussetti A; Jiménez-Ubieto A; Sancho JM; Sureda A; Pérez A; Barba P; Kwon M; Martín García-Sancho A
    Transplant Cell Ther; 2023 Dec; 29(12):747.e1-747.e10. PubMed ID: 37659694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience.
    Casadei B; Argnani L; Guadagnuolo S; Pellegrini C; Stefoni V; Broccoli A; Nanni L; Morigi A; Lolli G; Guarino M; Spinardi L; Pierucci E; Fanti S; Bartoletti M; Dicataldo M; Sabattini E; Bonifazi F; Zinzani PL
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
    St-Pierre F; Gordon LI
    Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
    Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
    J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models.
    Bansal A; Sullivan SD; Lin VW; Purdum AG; Navale L; Cheng P; Ramsey SD
    Med Decis Making; 2019 Apr; 39(3):294-298. PubMed ID: 30819038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma.
    Iacoboni G; Villacampa G; Martinez-Cibrian N; Bailén R; Lopez Corral L; Sanchez JM; Guerreiro M; Caballero AC; Mussetti A; Sancho JM; Hernani R; Abrisqueta P; Solano C; Sureda A; Briones J; Martin Garcia-Sancho A; Kwon M; Reguera-Ortega JL; Barba P;
    Cancer Med; 2021 May; 10(10):3214-3223. PubMed ID: 33932100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma.
    Fahrmann JF; Saini NY; Chia-Chi C; Irajizad E; Strati P; Nair R; Fayad LE; Ahmed S; Lee HJ; Iyer S; Steiner R; Vykoukal J; Wu R; Dennison JB; Nastoupil L; Jain P; Wang M; Green M; Westin J; Blumenberg V; Davila M; Champlin R; Shpall EJ; Kebriaei P; Flowers CR; Jain M; Jenq R; Stein-Thoeringer CK; Subklewe M; Neelapu SS; Hanash S
    Cell Rep Med; 2022 Nov; 3(11):100720. PubMed ID: 36384092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review.
    Sussman M; Crivera C; Benner J; Adair N
    Adv Ther; 2021 Aug; 38(8):4178-4194. PubMed ID: 34251651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
    Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
    Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.